Immodulon presents Phase II clinical data of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

IMM-101 in combination with nivolumab was well-tolerated and demonstrated encouraging efficacy data Primary endpoints were met, including 73% Overall Response Rate (ORR) in treatment-naïve patients with advanced melanoma Uxbridge, UK, 7 June 2022 – Immodulon...

Immodulon announces Notices of Allowance and Intention to Grant for four patent applications related to IMM-101 in combination with immune checkpoint inhibitors in US, Japan and Europe

Claims cover methods of treating cancer with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies Uxbridge, UK, 8 March 2021 – Immodulon, the immuno-oncology company, today announced that it has received Notices of Allowance from the U.S. Patent...